Celldex’s mAb fails to show benefit in Phase II prurigo nodularis trial
Celldex’s stock is expected to drop when markets open on 22 July following the trial’s failure.
22 July 2026
22 July 2026
Celldex’s stock is expected to drop when markets open on 22 July following the trial’s failure.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.